FDA warns Dr. Maria Carballosa over failure to retain clinical trial records for an investigational drug.
What happened
FDA inspected Power MD Clinical Research Institute in Hialeah, Florida, from March 4 to 6, 2025, as part of its Bioresearch Monitoring Program. FDA found that Dr. Carballosa did not retain study-drug disposition records or adequate and accurate case histories, including signed and dated informed consent forms and case report forms, for Protocol (b)(4). She said the records may have moved with Power MD's owner but provided no evidence of FDA notification or permission, and she did not know where the records were or whether they existed.
What FDA found
Failed to retain records showing the study drug's disposition, including dates, quantity, and use by subjects.
21 CFR 312.62(c)Failed to retain adequate and accurate case histories, including signed and dated informed consent forms, case report forms, and supporting data.
21 CFR 312.62(c)
What FDA wants
Within 15 business days, FDA asks Dr. Carballosa to notify the office in writing of actions taken to prevent similar violations and to explain how study records will be retained as required.
Who should pay attention
- clinical investigators in FDA-regulated trials
- sponsors relying on site records for applications
- research sites and CROs that archive trial records
This is a summary. Read the original letter on fda.gov.